Publications by authors named "E J Schiller"

Multimodal models have become increasingly important as they surpass single-modality approaches on diverse tasks ranging from question-answering to disease diagnosis. Despite the importance of multimodal learning, existing efforts focus on vision-language applications, where the number of modalities rarely exceeds four (images, text, audio, video). However, data in healthcare domain, may include many more modalities like X-rays, PET scans, MRIs, genetic screening, genomic data, and clinical notes, creating a need for both efficient and accurate data integration.

View Article and Find Full Text PDF

Introduction: There are many recognised benefits of public involvement, including more relevant research. The COVID-19 pandemic highlighted the existing health inequalities and disparities in access to care and treatment for under-served groups, necessitating meaningful and sustainable approaches to engaging them in health research. However, there is limited guidance to suggest what groundwork and processes are necessary for initiating such projects.

View Article and Find Full Text PDF
Article Synopsis
  • SARS-CoV-2 infection during pregnancy can have serious consequences for both mothers and newborns, making vaccination a crucial preventative tool.
  • Early clinical trials did not include pregnant women, but later studies confirmed the effectiveness and short-term safety of mRNA vaccines in this group.
  • There is limited information on how vaccine mRNA spreads during pregnancy and breastfeeding, with new evidence showing it's present in breast milk, raising concerns about its potential impact on the placenta and fetus that need further exploration.
View Article and Find Full Text PDF

In order to achieve the goals of the Medical Informatics Initiative (MII), staff with skills in the field of medical informatics and data science are required. Each consortium has established training activities. Further, cross-consortium activities have emerged.

View Article and Find Full Text PDF
Article Synopsis
  • In July 2023, the FDA fully approved lecanemab for treating mild cognitive impairment and mild Alzheimer's disease, providing hope for patients due to the lack of existing options.
  • The review details FDA treatment guidelines, other anti-amyloid agents, and relevant drug information for healthcare providers, discussing clinical trial results and their implications.
  • While lecanemab shows promise as a treatment, further research is needed to understand its long-term effects, optimal use with other therapies, and its role in lifestyle interventions for Alzheimer's disease.
View Article and Find Full Text PDF